Page 5 of 6
RSC Advances
DOI: 10.1039/C4RA12782J
Based on the literature reports,19,2a,2e,14 a plausible mechanism
for the formation of 3ꢀphenylmethyleneisoindolinꢀ1ꢀone is
outlined in Scheme 4. Initially a Cu(I) intermediate (A) is formed
was then cooled to room temperature, admixed with water (5 mL)
and the product was extracted with ethyl acetate (2 x 20 mL). The
organic phase was dried over anhydrous sodium sulphate and
with phenyl propiolic acid (a). This Cu(I) species via a 55 concentrated in vacuo. The crude product was purified over a
5
decarboxylative path gives Cuꢀalkynylide species (B) which
undergoes oxidative addition with 2ꢀbromobenzamide (1) to
produce Cu(III) intermediate (C). Reductive elimination of Cu
from (C) gives the orthoꢀalkynylated product (D). Deprotonation
of the amide N−H of the intermediate (D) and subsequent
column of silica gel and eluted with (19:1 hexane / ethyl acetate
to give (Z)ꢀ3ꢀbenzylideneꢀ2ꢀphenylisoindolinꢀ1ꢀone (1a) (102.5
mg, 69% yield).
Acknowledgement
10 hydroamination20 of C−C triple bond promoted by coꢀordination
of Cu(I) with the alkynyl group results in the formation of 3ꢀ
phenylmethyleneisoindolinꢀ1ꢀone (1a) via the intermediacy of
(E) along with regeneration of Cu(I). The formation of
intermediate species (A), (B), (C) and (D) have been detected by
15 the ESI/MS analysis of reaction aliquot which support the
proposed mechanism in Scheme 4 (see Supporting Information
[SI]).
60 B. K. P acknowledges the support of this research by the
Department of Science and Technology (DST) (SR/S1/OCꢀ
79/2009), New Delhi, and the Council of Scientific and Industrial
Research (CSIR) (02(0096)/12/EMRꢀII). AG, and GM thank
UGC for fellowships. Thanks are due to Central Instruments
65 Facility (CIF) IIT Guwahati for NMR spectra and DSTꢀFIST for
XRD facility.
References
70 1. (a) N. Rodrìguez and L. J. Goossen, Chem. Soc. Rev., 2011, 40, 5030;
(b) J. D. Weaver, A. Recio, A. J. Grenning and J. A. Tunge, Chem.
Rev., 2011, 111, 1846; (c) J. Cornella and I. Larrosa, Synthesis, 2012,
44, 653.
2. (a) D. Zhao, C. Gao, X. Su, Y. He, J. You and Y. Xue, Chem.
75
Commun., 2010, 46, 9049; (b) W.ꢀW. Zhang, X.ꢀG. Zhang and J.ꢀH.
Li, J. Org. Chem., 2010, 75, 5259; (c) J. Moon, M. Jang and S. Lee,
J. Org. Chem., 2009, 74, 1403; (d) W. Jia and N. Jiao, Org. Lett.,
2010, 12, 2000; (e) S. Ranjit, Z. Duan, P. Zhang and X. Liu, Org.
Lett., 2010, 12, 4134.
80 3. (a) N. G. Kundu, M.W. Khan and R. Mukhopadhyay, Tetrahedron,
1999, 55, 12361; (b) T. Yao and R. C. Larock, J. Org. Chem., 2005,
70, 1432; (c) S. Mehta, J. P. Waldo and R. C. Larock, J. Org. Chem.,
2009, 74, 1141; (d) S. F. Vasilevsky, T. F. Mikhailovskaya, V. I.
Mamatyuk, G. E. Salnikov, G. A. Bogdanchikov, M. Manoharan and
85
I. V. Alabugin, J. Org. Chem., 2009, 74, 8106.
20
4. (a) G. Blasko´, D. J. Gula and M. J. Shamma, Nat. Prod., 1982, 45,
105; (b) Laboratori Baldacci S. p. A. JP 59046268, Chem. Abstr.,
1984, 101, 54922; (c) Y. Kato, H. Ebiike, K. Achiwa, N. Ashizawa,
T. Kurihara and F. Kobayashi, Chem. Pharm. Bull., 1990, 38, 2060;
(d) Y. Kato, M. Takemoto and K. Achiwa, Chem. Pharm. Bull.,
1999, 47, 529; (e) Y.ꢀC. Chia, F.ꢀR. Chang, C.ꢀM. Teng and Y.ꢀC.
Wu, J. Nat. Prod., 2000, 63, 1160; (f) H. M. Botero Cid, C. Tra¨nkle,
K. Baumann, R. Pick, E. MiesꢀKlomfass, E. Kostenis, K. Mohr and
U. Holzgrabe, J. Med. Chem., 2000, 43, 2155; (g) A. Couture, E.
Deniau, P. Grandclaudon, H. RybalkoꢀRosen, S. Le´once, B. Pfeiffer
and P. Renard, Bioorg. Med. Chem. Lett., 2002, 12, 3557; (h) B.
Hulin, J. C. Parker and D. W. Piotrowski, US2005234065; (i) K.
Toyooka, N. Kanamitsu, M. Yoshimura, H. Kuriyama and T.
Tamura, WO2004048332. (j) J. Weinstock, J. P. Hieble and J. W.
Wilson, Drugs Future, 1985, 10, 645; (k) G. A. Cordell, In The
Alkaloids: Chemistry and Pharmacology; Academic: San Diego,
1998; Vol. 50; (l) K. Achinami, N. Ashizawa and F. Kobayashi, Jpn
Patent JP 03 1991, 133, 955.
5. (a) L. Castedo, E. Guitián, J. M. Saá and R. Suau, Heterocycles,
1982, 19, 279; (b) Y. Kato, M. Takemoto and K. Achiwa, Chem.
Pharm. Bull., 1993, 41, 2003; (c) E. Mertz, S. Mattei and S. C.
Zimmerman, Bioorg. Med. Chem., 2004, 12, 1517; (d) A. Moreau, A.
Couture, E. Deniau and P. Grandclaudon, J. Org. Chem., 2004, 69,
4527; (e) M. Lamblin, A. Couture, E. Deniau and P. Grandclaudon,
Tetrahedron, 2006, 62, 2917; (f) M. Lamblin, A. Couture, E. Deniau
and P. Grandclaudon, Org. Biomol. Chem., 2007, 5, 1466; (g) T. Lei,
Y. Cao, Y. Fan, C.ꢀJ. Liu, S.ꢀC. Yuan and J. Pei, J. Am. Chem. Soc.,
2011, 133, 6099.
Scheme 5. Plausible mechanism for the formation of 3ꢀ
methyleneisoindolinꢀ1ꢀone.
However an alternative mechanism involving initial
25 oxidative addition of Cu(I) with 2ꢀhalobenzamide to give
intermediate (A′) as proposed in Scheme 5 cannot be completely
ruled out. Intermediate (A′) couples with phenylpropiolic acid (a)
to give intermediate (B′). Loss of CO2 from intermediate (B′)
would give intermediate (C) which eventually lead to the
30 formation of desired product (1a) as shown in Scheme 4.
90
95
Conclusion
100
105
110
115
In conclusion, we have developed a Cu(I)ꢀcatalysed synthesis
35 of
substituted
3ꢀmethyleneisoindolinꢀ1ꢀones
involving
decarboxylative crossꢀcoupling of 2ꢀhalobenzamides with aryl
alkynyl acids followed by 5ꢀexoꢀdig heteroannulation. In this
transformation alkynyl acids have been utilised to generate
alkyne intermediate for the synthesis of this important
40 heterocycle scaffold. While reactions of 2ꢀiodo benzamides
proceeded without ligand, for 2ꢀbromo subtrates the assistance of
a ligand is essential.
General procedure for the synthesis of (Z)ꢀ3ꢀbenzylideneꢀ2ꢀ
45 phenylisoindolinꢀ1ꢀone (1a)
6. (a) A. Couture, E. Deniau and P. Grandclaudon, Tetrahedron, 1997,
53, 10313; (b) A. Couture, E. Deniau, P. Grandclaudon and C.
Hoarau, Tetrahedron, 2000, 56, 1491; (c) V. Rys, A. Couture, E.
Deniau and P. Grandclaudon, Tetrahedron, 2003, 59, 6615; (d) M. A.
ReyesꢀGonzalez, A. ZamudioꢀMedina and M. Ordonez, Tetrahedron
Lett., 2012, 53, 5756.
To a solution of 2ꢀbromobenzamide (1) (138 mg, 0.5 mmol) in
DMSO (2 mL) was added CuI (9.5 mg, 0.05 mmol), 1,10ꢀphen (9
mg, 0.05 mmol), Cs2CO3 (245 mg, 0.75 mmol), phenyl propiolic
50 acid (a) (87.6 mg, 0.6 mmol) and the resultant mixture was stirred
o
in a preheated oil bath at 120 C for 2 h. The reaction mixture
4
| Journal Name, [year], [vol], 00–00
This journal is © The Royal Society of Chemistry [year]